A case of sensory ataxic Guillain-Barré syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer)

QJM. 2022 Jan 21;115(1):25-27. doi: 10.1093/qjmed/hcab296.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Guillain-Barre Syndrome*
  • Humans
  • Immunoglobulin G
  • RNA, Messenger
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • Immunoglobulin G
  • RNA, Messenger
  • BNT162 Vaccine